Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lack of tacrolimus-induced cardiomyopathy
Autore:
Coley, KC; Verrico, MM; McNamara, DM; Park, SC; Cressman, MD; Branch, RA;
Indirizzi:
Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA Univ Pittsburgh Pittsburgh PA USA 15261 erapeut, Pittsburgh, PA 15261 USA Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA Univ Pittsburgh Pittsburgh PA USA 15260 Sch Med, Pittsburgh, PA 15260 USA Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA Univ Pittsburgh Pittsburgh PA USA 15260 armacol, Pittsburgh, PA 15260 USA
Titolo Testata:
ANNALS OF PHARMACOTHERAPY
fascicolo: 9, volume: 35, anno: 2001,
pagine: 985 - 989
SICI:
1060-0280(200109)35:9<985:LOTC>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
HYPERTROPHIC CARDIOMYOPATHY; TRANSPLANT RECIPIENTS; PREVALENCE; POPULATION;
Keywords:
cardiomyopathy; immunosuppressive agents; tacrolimus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
9
Recensione:
Indirizzi per estratti:
Indirizzo: Coley, KC Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 921 Salk Hall, Pittsburgh, PA 15261 USA Univ Pittsburgh 921 Salk Hall Pittsburgh PA USA15261 15261 USA
Citazione:
K.C. Coley et al., "Lack of tacrolimus-induced cardiomyopathy", ANN PHARMAC, 35(9), 2001, pp. 985-989

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) has been reported in pediatric transplant patients receiving tacrolimus. It is unclear whether tacrolimus is associated with HCM in adult transplant recipients. OBJECTIVE: To determine the prevalence of HCM in noncardiac adult transplant patients receiving tacrolimus. METHODS: A retrospective analysis of nonheart transplant recipients who received tacrolimus at our institution from January 1982 to April 1996 was conducted. Patients with left-ventricular hypertrophy (LVH) defined as a posterior or septal wall thickness greater than or equal to1.3 cm by echocardiography (ECHO) were independently evaluated. RESULTS: There were 3609 patients who met entry criteria including 2257 liver, 1333 kidney, and 19 other organ transplants. Of the 502 patients who had undergone ECHOs after transplantation, 171 had LVH. The etiology of LVH was categorized as valvular disease (36%), hypertensive disease (29%), ischemic heart disease (17%), or multifactorial (15%). There were six patients in whom, after detailed chart review, no underlying cause of LVH was evident. Five of these patients had HCM, representing an overall prevalence of 0.1% in the entire group of tacrolimus-treated patients, and 1% in patients referred for ECHO. CONCLUSIONS: The prevalence of HCM in our tacrolimus-treated adult transplant population is similar to that reported in general population studies. These data suggest that tacrolimus is not a risk factor for HCM in adult transplant recipients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 19:04:53